New MRI method could prevent unnecessary treatment changes in rectal cancer patients
NCT ID NCT07381322
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to improve how doctors tell the difference between real tumor growth and pseudoprogression (a harmless, temporary increase in tumor size) after immunotherapy for rectal cancer. Researchers will use multiple MRI scans and blood tests from 300 participants to build a model that more accurately predicts pseudoprogression. The goal is to help patients avoid unnecessary changes in their cancer treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sixth affiliated hospital, Sun Yat-sen University
NOT_YET_RECRUITINGGuangzhou, Guangdong, 510655, China
-
Xinyi People's hospital
RECRUITINGMaoming, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital nurse companion: could an app ease the burden of chronic illness?
- Which rectal cancer surgery preserves quality of life better? a study investigates
- AI as a surgical Co-Pilot: predicting difficulty in rectal cancer
- Can AI learn to grade endoscopy quality from video?
- Can precision protons spare rectal cancer patients from harsh side effects?
- A new radiation combo may spare the rectum in early cancer